Analysts tracking consumer health product firms in the US anticipatevApril-June results lower than a year ago across most businesses. While some results will be lower on comparisons with strong growth in 2023, others will reflect a slow allergy season, retailers’ inventories remaining high as consumer spending slows or firms continuing to recover from supply chain problems.

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

DeSimone returns as Herbalife CFO; Mannatech CEO Bala leaving on 1 April with Fredrick moving to post; CHPA lifetime achievement award for former Perrigo exec Needham; comedian hacks healthy nutrition for Quest; “John Wick” inspires Jacked; NBA player assists Earth Splendor; HRG owner group expands with HR director.

Since closing at a 14-year low of $8.07 the day of the execs’ transactions, Herbalife shares trend steadily up from close of $8.26 on 20 February to $8.83 on 29 February. Some execs sell back some shares on 25 February at $8.67.